ClinicalTrials.gg
RecruitingNCT07057596NEO-TBUpdated Sep 15, 2026

Neoadjuvant Tebentafusp in Patients With Metastatic Uveal Melanoma

A Phase 2 interventional study of Tebentafusp in Mestastatic Uveal Melanoma, sponsored by Grupo Español Multidisciplinar de Melanoma. Recruiting at 4 sites in 2 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-09-15.

Sponsored by Grupo Español Multidisciplinar de Melanoma · Phase 2, Interventional, and Treatment

How we know

From the registry’s dates

  • Started Jul 2025; still recruiting 1 year 4 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
19
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 11 studies in Melanoma by Grupo Español Multidisciplinar de Melanoma — 2 open to participants now, 4 under way, none of them phase 3. Melanoma · Grupo Español Multidisciplinar de Melanoma.

Started
2025
with 2 others
Phase 2
8 of 11
2 open now
Registered
11th of 11
by date

Among the 11 studies in Melanoma by Grupo Español Multidisciplinar de Melanoma, this one is one of 3 that started in 2025, is one of 8 in phase 2, and was the 11th registered.

Melanoma

3,374 studies on the registry are indexed under Melanoma; 579 are open to participants now.

Browse Melanoma studies →

Open to participants now

2 of the 11 studies in Melanoma by Grupo Español Multidisciplinar de Melanoma are open now, in 2 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 2 open studies →

Where they have run

Who these studies take

Of the 467 Melanoma studies recruiting now, 379 (81%) set no upper age limit and 49 (10%) stop at 75 or younger; 47 take children under 18; 29 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 11 studies in Melanoma by Grupo Español Multidisciplinar de Melanoma, or all of them as a file.
02

Study summary

Uveal melanoma (UM) is a rare type of melanoma, with an incidence of 4.4 cases per million in Europe each year. During recent years, different treatment approaches have been tested in patients with metastatic UM. Responses have been reported primarily with localized treatment in patients with a limited number of liver metastases. In cases of diffuse liver involvement or extrahepatic disease, systemic therapies are justified. However, to date, systemic therapies such as targeted therapy with selumetinib or conventional chemotherapy have failed in metastatic UM.

Neo-TB is a Phase II, single arm, multicentre clinical trial designed to evaluate efficacy and safety of tebentafusp used as a single agent in patients with metastatic uveal melanoma with resectable / potentially resectable liver metastasis and absence of extrahepatic disease.

The main questions it aims to answer are:

  1. Which is the capacity of tebentafusp used as a single agent to generate pathological complete response (pCR) in patients with metastatic uveal melanoma with resectable liver metastasis and absence of extrahepatic disease.
  2. Which is the efficacy of tebentafusp used as a single agent to maintain disease control and delay relapse / progression.
  3. Which is the safety of tebentafusp used as a single agent in metastatic uveal melanoma.

The main hypothesis is that neoadjuvant treatment with Tebentafusp could achieve ≥20% pathological complete response (pCR) in patients with metastatic uveal melanoma with resectable/potentially resectable liver metastasis and absence of extrahepatic disease. It is assumed that untreated patients would not present a pCR (response rate of ≤1%).

Read the detailed description
  1. RACIONAL Tebentafusp has demonstrated efficacy and safety and is indicated as monotherapy for the treatment of adult patients with human leukocyte antigen (HLA)-A*02:01-positive unresectable or metastatic uveal melanoma. The main hypothesis is that neoadjuvant treatment with Tebentafusp could achieve ≥20% pathological complete response (pCR) in patients with metastatic uveal melanoma with resectable or potentially resectable liver metastasis and absence of extrahepatic disease.
  2. OBJECTIVES Primary Objective: to evaluate the ability of tebentafusp used as a single agent to generate pathological complete responses (pCR) in patients with metastatic uveal melanoma with resectable / potentially resectable liver metastases and absence of extrahepatic disease.

    Secondary objectives: to assess efficacy and safety of tebentafusp used as a single agent to maintain disease control and delay relapse / progression.

    Exploratory objectives:

    • Study mechanisms of resistance to tebentafusp.
    • Study correlation between pathological response and circulating tumor DNA (ctDNA) dynamics or circulating tumor cells (CTCs).
    • Evaluate dynamics in T-cell receptor (TCR) populations and peripheral lymphocytes memory cells in blood samples before/after Tebentafusp and in the prospective fresh samples from liver resections.
  3. Primary Endpoint The primary endpoint for NEO-TB trial is the pathological complete response (pCR) rate, defined as no presence of residual disease assessed by biopsy or surgical resection at 7 months (+/-1 month) after the start of the scheduled treatment with tebentafusp.
  4. Secondary Endpoints

    • Objective response rate (ORR) according to RECIST 1.1
    • Disease control rate (DCR) according to RECIST 1.1
    • Relapse-free survival (RFS) according to RECIST 1.1
    • Event-free survival (EFS)
    • Overall survival (OS)
    • Adverse events (AE)
    • Treatment-related AEs (TRAEs)
    • Molecular biomarkers determined from liver biopsies at baseline and fresh samples from liver resections in lesions with viable tumors and samples of peripheral blood.
  5. Study Design

    NEO-TB is a non-randomized, single arm, multi-centre, phase II study of Tebentafusp monotherapy in subjects with resectable / potentially resectable disease within the liver and absence of extra-liver disease. The Neo-TB study is divided into 4 phases: Screening, Treatment, Surgery and Follow-up. After informed consent is obtained, subjects will enter the Treatment phase.

    All patients will undergo periodic tumor assessments by CT or MRI scan every 8 weeks ± 7 days from the start of study treatment and during the first 48 weeks of study. Tumor assessments will be performed every 12 weeks ± 7 days thereafter until relapse or patient withdrawal. After surgery, CT or MRI scans will be performed every 12 weeks ± 7 days thereafter, regardless of time after study inclusion. Further CT/MRI scans could be performed upon suspicion of disease relapse according to standard clinical practice and physician criteria. The study includes the collection of tumor and blood samples for the determination of exploratory endpoints

  6. Study Population The trial will enroll 19 patients; male and female, ≥ 18 years, with ECOG PS 0-1 patients with metastatic uveal melanoma (HLA)-A*02:01 positive who have resectable or potentially resectable metastatic lesions only in the liver. Patients with extrahepatic disease are not eligible. Patients will have not received previously other anti-tumor treatments.
  7. Study Treatment

    Patients will receive tebentafusp intravenously (IV) weekly for 6 months with liver directed imaging every 2 months to identify rapid progressors. Rapid progressors will discontinue tebentafusp and have surgical resection if considered feasible. After 6 months, patients with complete response (CR) according to RECIST will continue tebentafusp therapy (surgery might be an option if deem appropriate by local PI); while patients achieving partial response or stable disease will be evaluated for tumor resection and will enter into Surgery phase. Surgery will be conducted 7 months (+/- 1 month). If PD occurs earlier surgery can happen earlier. After surgery, patients without pCR or R0 surgery will maintain tebentafusp until disease relapse, unacceptable toxicity or patient withdrawal. Patients with pCR and R0 will continue tebentafusp therapy for 1 additional year or until disease relapse, unacceptable toxicity or patient withdrawal

  8. Ethical Considerations Patients with metastatic uveal melanoma have limited therapeutic options. Clinical guidelines recommend considering clinical trials.

Tebentafusp is approved for use as monotherapy in patients with uveal melanoma whose tumors are positive for (HLA)-A*02:01. In the phase 3 clinical trial, tebentafusp showed a significant improvement in overall survival compared to other standard therapies and therefore it is considered the treatment of choice for patients with (HLA)-A*02:01 positive tumors.

NEO-TB aims to use tebentafusp in the pathology for which it is indicated, with the only modification of combining its administration with surgical resection in patients already or potentially candidates for surgery, aiming to evaluate the pathological response. The guidelines also allow this multimodal treatment strategy with tebentafusp and surgery, so the trial could in some way consider the proposed intervention as low impact. Patients will be closely monitored, following an adaptive strategy to allow surgery if necessary, avoiding delays that limit tumor resection. Tebentafusp is the standard therapy for these patients, so its administration in the context of this trial is not expected to increase the risks already described associated with this treatment. Given the mechanism of action of tebentafusp, an increase in its toxicity due to the combination with surgery is not expected. Immunotherapies in combination with surgery are used in the perioperative setting as neoadjuvant and adjuvant strategies in patients with cutaneous melanoma and are safe. However, there is no published data with patients treated with tebentafusp in this context.

Given the limited therapeutic options and the current evidence and rationale for the use of tebentafusp and surgery, the risk-benefit ratio of this trial is considered positive. The potential benefit outweighs the risks

03

Conditions studied

  • Mestastatic Uveal Melanoma

Keywords

  • Melanoma
  • Tebentafusp
  • Metastatic
  • Neoadjuvant
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Patients must have confirmed uveal melanoma with Human leukocyte antigen-A*0201 positive determined by local assay.
  2. Patients with histologically proven metastatic uveal melanoma in the liver with reectable or potentially resectable liver metastases evaluated by imaging in a multidisciplinary committee. Metastasis can be considered resectable by any of the following:

    1. Minor resection (i.e., less than a hemihepatectomy)
    2. Major resection (i.e., hemihepatectomy or extended hepatectomy)
    3. Bilobar resection (including atypical resection).
  3. Must meet the following criteria related to prior treatment:

    1. No prior systemic therapy in the metastatic or advanced setting including chemotherapy, immunotherapy, or targeted therapy.
    2. No prior local, liver-directed therapy including chemotherapy, radiotherapy, radiofrequency ablation (RFA), or embolization.
    3. Prior or adjuvant therapy is allowed provided it was administered in the curative setting in patients with localized disease.
  4. Institutional Review Board (IRB)/Independent Ethics Committee (IEC) approved written and signed .
  5. Male or female patients age ≥ 18 years of age at the time of informed consent.
  6. Performance Status (ECOG-PS) 0-1
  7. Adequate organ function as defined below (without transfusion):

    1. ≥9.0 g/dL.
    2. (ANC) >1.5 x 109/L (> 1500 per mm3).
    3. count ≥ 100 x 109/L (>75,000 per mm3).
    4. Serum ≤1.5 x institutional (ULN). This will not apply to patients with confirmed Gilbert's syndrome (persistent or recurrent hyperbilirubinemia that is predominantly unconjugated in the absence of hemolysis or hepatic pathology), who will be allowed only in consultation with the Coordinating Investigator.
    5. Both and ALT must be \< 5 x ULN.
    6. ⩾50 ml/min calculated by Cockcroft-Gault (Table 4) or another validated method.
    7. Potassium, magnesium, corrected calcium or phosphate abnormality of National Cancer Institute (NCI CTCAE) > grade 1.

Exclusion criteria

Exclusion Criteria:

  1. Presence of extrahepatic disease.
  2. Patients with concomitant other than non-melanoma skin cancer, or superficial bladder cancer controlled with local treatment. Patients with prior malignancy must have been disease free for 5 years.
  3. History of severe reactions (eg, anaphylaxis) to other biologic drugs or monoclonal antibodies.
  4. cardiac disease or impaired cardiac function, including any of the following:

    1. Clinically significant and/or uncontrolled heart disease such as congestive heart failure ( grade ≥ 2), uncontrolled hypertension, or clinically significant arrhythmia currently requiring medical treatment.
    2. > 470 msec on screening (ECG) or congenital long QT syndrome.
    3. Acute myocardial infarction or unstable angina pectoris \< 6 months prior to Screening.
  5. History of adrenal insufficiency.
  6. History of interstitial lung disease
  7. History of pneumonitis that required treatment or current pneumonitis
  8. History of colitis or inflammatory bowel disease.
  9. Active infection requiring systemic antibiotic therapy. Patients requiring systemic antibiotics for infection must have completed therapy at least 1 week prior to the first dose of study drug.
  10. Known history of (HIV) infection. Testing for HIV status is not necessary unless clinically indicated or if required by local regulations.
  11. Active virus (HBV) or virus (HCV) infection per institutional protocol. Testing for HBV or HCV status is not necessary unless clinically indicated.
  12. Previous treatment with Tebentafusp.
  13. Patients receiving systemic steroid therapy or any other medication at any dose level. Local steroid therapies (eg, otic, ophthalmic, intra-articular or inhaled medications) are acceptable.
  14. Major surgery within 2 weeks of the first dose of study drug (minimally invasive procedures such as bronchoscopy, tumor , insertion of a central venous access device, and insertion of a feeding tube are not considered major surgery and are not exclusionary).
  15. Use of hematopoietic colony-stimulating growth factors (e.g., G-CSF, GMCSF, M-CSF) ≤ 2 weeks prior to the start of study drug. Patients must have completed therapy with hematopoietic colony-stimulating factor at least 2 weeks before the first dose of study drug is given. An erythroid-stimulating agent is allowed as long as it was initiated at least 2 weeks prior to the first dose of study treatment and the patient is not red blood cell transfusion dependent.
  16. Hypersensitivity to the active substance of tebentafusp or to any of its , including: Citric acid monohydrate (E330) Di-sodium hydrogen phosphate (E339) Mannitol (E421) Trehalose Polysorbate 20 (E432).
  17. Patients whose circumstances will not permit study completion or adequate follow up.
  18. Pregnant, likely to become pregnant, or lactating women (where pregnancy is defined as the state of a female after conception and until the termination of gestation).
  19. Women of who are sexually active with a non-sterilized male partner, defined as all women physiologically capable of becoming pregnant, unless they are using highly effective during study treatment, and must agree to continue using such precautions for 1 week after the final dose of product. Highly effective methods of contraception are described in Appendix 5.
  20. Male patients must be surgically sterile or use double barrier contraception methods from enrollment through treatment and for 1 week following administration of the last dose of study drug.
Terms in these criteria, in plain language(29)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Adjuvant and neoadjuvant

Neoadjuvant treatment is given before the main treatment (usually surgery), often to shrink a tumor. Adjuvant treatment is given after it, to lower the chance of the cancer coming back.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Absolute neutrophil count (ANC)

The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.

It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

CTCAE grade

The US National Cancer Institute’s scale of how severe an adverse event is — any unwanted medical event during a study, such as a symptom, an illness or an abnormal test result, whether or not a treatment caused it. Whether it did is judged separately.

1
Mild.
2
Moderate.
3
Severe.
4
Life-threatening.
5
Death due to the event.

“Side effects of earlier treatment resolved to grade 1 or less” means they have settled to mild or gone.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
19 participants (estimated)

Study arms

  • Experimental
    Neoadjuvant Tebentafusp

    Patients will receive tebentafusp intravenously (IV) weekly for 6 months with liver directed imaging every 2 months to identify rapid progressors. Rapid progressors will discontinue tebentafusp and have surgical resection if considered feasible. After 6 months, patients with complete response (CR) according to RECIST will continue tebentafusp therapy. Surgery might be an option if deem appropriate by local PI); while patients achieving partial response or stable disease will be evaluated for tumor resection and will enter into Surgery phase. Surgery will be conducted 7 months (+/- 1 month). If progressioh disease (PD) occurs earlier surgery can happen earlier. After surgery, patients without pCR or R0 surgery will maintain tebentafusp until disease relapse, unacceptable toxicity or patient withdrawal. Patients with pCR and R0 will continue tebentafusp therapy for 1 additional year or until disease relapse, unacceptable toxicity or patient withdrawal.

    Drug: Tebentafusp

Interventions

  • Patients will receive tebentafusp intravenously (IV) weekly for 6 months with liver directed imaging every 2 months to identify rapid progressors. Tebentafusp will be administered at 20 micrograms on W1D1, 30 micrograms on W2D1, and 68 micrograms once every week thereafter. After 6 months, patients with complete response (CR) according to RECIST will continue tebentafusp therapy (surgery might be an option if deem appropriate by local PI); while patients achieving partial response or stable disease will be evaluated for tumor resection and will enter into Surgery phase. Surgery will be conducted 7 months (+/- 1 month). If progressioh disease (PD) occurs earlier surgery can happen earlier. After surgery, patients without pCR or R0 surgery will maintain tebentafusp until disease relapse, unacceptable toxicity or patient withdrawal. Patients with pCR and R0 will continue tebentafusp therapy for 1 additional year or until disease relapse, unacceptable toxicity or patient withdrawal.

06

What researchers measure

Primary outcomes

  1. Pathological complete response (pCR) rate

    Pathological complete response (pCR) rate, the primary efficacy endpoint: Defined as the rate of patients with metastatic uveal melanoma with resectable / potentially resectable liver metastasis and free of extrahepatic disease, who have no presence of residual disease assessed by biopsy or surgical resection at 7 months (+/- 1 month) after the start of the scheduled treatment with tebentafusp. pCR will be assessed locally on tumor samples from gross resection or biopsies obtained at 7 months (+/- 1 month) after the start of tebentafusp.

    Time frame: Throughout the study period, at 7 months (+/- 1 month) from the start of treatment]

Secondary outcomes

  1. Objective response rate (ORR) of neoadjuvant tebentafusp

    Assessed by the investigator through imaging follow-up (CT scan/MRI) using RECIST 1.1 up to surgical intervention. This will be considered as the percentage/proportion of patients with complete response (CR) or partial response (PR) as their overall best response throughout the study period. Objective responses will be assessed locally by the investigator according to RECIST, version 1.1, and indicating the change in size of tumors as compared with baseline, before the first dose of study treatment.

    Time frame: Throughout the study period, at 6 months from the start of treatment

  2. Disease control rate (DCR) of neoadjuvant tebentafusp

    Percentage/proportion of patients with complete response (CR) or partial response (PR), according to ORR definition for the trial, or maintained stable disease (SD) as their overall best response, assessed by imaging follow-up (CT scan/MRI) and RECIST 1.1 criteria. Stable disease should be maintained for at least 4 months to be considered as a DCR event. DCR will be assessed locally up to surgical intervention.

    Time frame: Throughout the study period, at 6 months from the start of treatment

  3. Relapse-free survival (RFS) at end of follow-up.

    Defined as the time from first study dosing date to the date of relapse after surgery according to RECIST 1.1 (Appendix 3) or death due to any cause. Patients who do not have surgical resection will be not evaluable for RFS endpoint. The RFS will be estimated by the Kaplan-Meier method. Patients alive and free of events at the date of the analysis will be censored at their last known tumor assessment. Patients who start a new treatment line without progression will be censored on the date of first dose of the subsequent anticancer treatment. RFS will be displayed graphically where appropriate. RFS will be calculated as median / mean (95% CI) and for different timepoints: * Proportion of patients without relapse at the end of follow-up. * Proportion of patients relapse-free at 6-months, 12-months and as deemed opportune by the time of the analysis The Cox proportional hazards model will be fitted to compute the hazard ratios on potential stratified groups if applicable.

    Time frame: Throughout the study period, approximate average of 24 months since the start of treatment

  4. Relapse-free survival (RFS) at at 6-months

    Defined as the time from first study dosing date to the date of relapse after surgery according to RECIST 1.1 (Appendix 3) or death due to any cause. Patients who do not have surgical resection will be not evaluable for RFS endpoint. The RFS will be estimated by the Kaplan-Meier method. Patients alive and free of events at the date of the analysis will be censored at their last known tumor assessment. Patients who start a new treatment line without progression will be censored on the date of first dose of the subsequent anticancer treatment. RFS will be displayed graphically where appropriate. RFS will be calculated as median / mean (95% CI) and for different timepoints: * Proportion of patients without relapse at the end of follow-up. * Proportion of patients relapse-free at 6-months, 12-months and as deemed opportune by the time of the analysis The Cox proportional hazards model will be fitted to compute the hazard ratios on potential stratified groups if applicable.

    Time frame: Throughout the study period, at 6 months from the start of treatment

  5. Relapse-free survival (RFS) at 12 months

    Defined as the time from first study dosing date to the date of relapse after surgery according to RECIST 1.1 (Appendix 3) or death due to any cause. Patients who do not have surgical resection will be not evaluable for RFS endpoint. The RFS will be estimated by the Kaplan-Meier method. Patients alive and free of events at the date of the analysis will be censored at their last known tumor assessment. Patients who start a new treatment line without progression will be censored on the date of first dose of the subsequent anticancer treatment. RFS will be displayed graphically where appropriate. RFS will be calculated as median / mean (95% CI) and for different timepoints: Proportion of patients relapse-free at 6-months, 12-months and as deemed opportune by the time of the analysis The Cox proportional hazards model will be fitted to compute the hazard ratios on potential stratified groups if applicable.

    Time frame: Throughout the study period, at 12 months from the start of treatment

  6. Overall survival (OS)

    Defined as the time elapsed from the first dose of study treatment until death from any cause. Patients alive and free of events at the date of the analysis will be censored at their last known contact. OS will be summarized using the Kaplan-Meier method and displayed graphically where appropriate. The Cox proportional hazards model will be fitted to compute the hazard ratios on potential stratified groups if applicable. OS will be calculated as median / mean (95% CI) and OS rate for different timepoints deemed appropriate at the time of the analysis (i.e.1-year OS rate) will also be calculated.

    Time frame: Throughout the study period, at 12 months from the start of treatment

07

Study locations

4 of 4 sites recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jul 2025 (actual). Primary completion is estimated for Dec 2027, 29 months after the start.

Of 277 non-industry phase 2 interventional studies under Melanoma, half reached primary completion within 67 months of starting (the median), counting those still running; a quarter within 41 and three quarters within 94. This study's planned 29 months is below that.

Counting every sponsor, half of 383 studies reached it within 53 months; a quarter within 32 and three quarters within 88.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 30, 2025
First posted
Jul 10, 2025
StartActual
Jul 18, 2025
Primary completionEst.
Dec 2027
CompletionEst.
Dec 2027
Last update
Sep 15, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 15, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07057596
Lead sponsor
Grupo Español Multidisciplinar de Melanoma
Responsible party
Sponsor
First posted
Jul 10, 2025
Start date
Jul 18, 2025
Primary completion
Dec 2027 (estimated)
Completion
Dec 2027 (estimated)
Last update
Sep 15, 2026

Study contacts

Federico Nepote
Contact
investigacion@mfar.net
934344412
Josep Maria Piulats, M.D., Ph.D.
Contact
Josep Maria Piulats, M.D., Ph.D.
study chair · Institut Catala d'Oncologia (ICO) Hospitalet

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Tebentafusp

Start the discussion